GENE ONLINE|News &
Opinion
Blog

2020-01-30| COVID-19

Update On 2019 Novel Coronavirus (2019-nCov): The Latest Progress In Vaccine Development And Treatment

by Sherry
Share To

Efforts Around the World to Develop Vaccines

Anthony Fauci, director of the US National Institute of Alliance and Infectious Diseases (NIAID), claims that they are confident to conduct a clinical phase I trial of a vaccine against the 2019-nCov in three months or less.

Johnson & Johnson has begun research on the virus and has applied its technology platform for rapid and large-scale production of optimized vaccine candidates. Meanwhile, Moderna and Inovio Pharma have announced plans to work together to develop a vaccine.

The Chinese and Russian governments are also attempting to co-develop a vaccine, and Beijing has transferred the 2019-nCoV genome data to Moscow. “Russian and Chinese experts have started developing vaccines against coronavirus,” the Russian Consulate in Guangzhou said in a statement.

Despite these accelerated developments, Novartis CEO Vas Narasimhan has shared a different view. He warned that it would take at least a year to develop an effective vaccine, and what is needed now is epidemiological control to reduce the outbreak.

Antiviral Drug

Gilead Sciences is evaluating whether its experimental RNA polymerase inhibitor remdesivir, originally developed for the treatment of Ebola, can be used against the coronavirus. Besides, AbbVie stated that it had donated USD 2 million worth HIV drug Kaletra (lopinavir / ritonavir) as an “experimental option” at the request of Chinese health authorities.

Cell Therapy

Cell therapy-related companies are not shying away from this fight either. Sorrento Therapeutics has announced a collaboration with Celularity for clinical development and manufacturing. The goal is to extend the therapeutic use of Celularity’s CYNK-001 (an allogeneic, off-the-shelf, placental-derived Natural Killer cell therapy) to treat and prevent coronavirus infections.

Related Article: Understanding the Scientific Challenges in Combating the New Coronavirus


References
  1. https://www.marketwatch.com/story/coronavirus-update-vaccine-expected-in-phase-1-trial-within-months-who-to-reconvene-on-thursday-2020-01-29
  2. https://www.jnj.com/latest-news/what-you-need-to-know-about-coronavirus-and-a-potential-johnson-johnson-vaccine
  3. https://www.nytimes.com/2020/01/28/health/coronavirus-vaccine.html
  4. https://www.washingtonpost.com/world/asia_pacific/coronavirus-china-live-updates/2020/01/29/d49b9194-423b-11ea-b503-2b077c436617_story.html
  5. https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus
  6. https://www.covaxx.com/press-release-jul15-1

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
The FDA Expands Use for Gilead Science’s HBV Treatment
2022-11-02
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!